

# **Role of IL-6 in GERD Patients with and without Obesity**

## **Thesis**

Submitted for partial fulfillment of Master Degree  
In Internal Medicine

**By**

**Eman Kamel Mohamed Ali**

M. B. B. CH.

Ain Shams University

**Under Supervision of**

**Prof. Dr. Mohsen Mostafa Maher**

Professor of Internal Medicine

Faculty of Medicine – Ain Shams University

**Prof. Dr. Tarek Mohamed Youssef**

Professor of Internal Medicine

Faculty of Medicine – Ain Shams University

**Ass.Prof. Dr. Wesam Ahmed Ibrahim**

Assistant professor of Internal Medicine

Faculty of Medicine – Ain Shams University

**Faculty of Medicine**

**Ain Shams University**

**2014**

**بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ**

قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا  
عَلَّمْتَنَا إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ

**صدق الله العظيم**

سورة البقرة آية (٣٢)



## Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and the Most Merciful.*

*I would like to express my sincere thanks and my deepest appreciation to **Prof. Dr. Mohsen Mostafa Maher**, Professor of internal medicine, Faculty of Medicine – Ain-Shams University for his supervision, guidance, valuable advice, helpful directions throughout the whole work,*

*My deepest gratitude and respect to **Dr. Tarek Mohamed Youssef**, Professor of Internal Medicine, Faculty of Medicine –Ain-Shams University, for his keen interest, constant support and continuous encouragement during the conduction of this work,*

*My extreme thanks to **Dr. Wesam Ahmed Ibrahim**, Assistant Professor of Internal Medicine, Faculty of Medicine –Ain-Shams University, for her sincere guidance and supervision.*

 **Eman Kamel Mohamed Ali**

# List of Contents

<i>Subject</i>	<i>Page No.</i>
List of Abbreviations.....	i
List of Tables.....	ii
List of Figures.....	iv
Introduction .....	5
Aim of the Work.....	7
Gastroesophageal Reflux Disease (GERD).....	8
Obesity.....	55
Interleukin-6 .....	118
Patients and Methods.....	124
Results.....	133
Discussion .....	149
Summary .....	158
Conclusion and Recommendations.....	162
References .....	163
Arabic Summary .....	—

## List of Abbreviations

<b>BMI</b>	: Body Mass Index
<b>CCK</b>	: Cholecystokinin
<b>CNS</b>	: Central nervous system
<b>DEXA</b>	: Dual-energy X-ray absorptiometry
<b>FDA</b>	: Food and drugs administration
<b>GABA</b>	: Gamma Amino Buteric Acid
<b>GERD</b>	: Gastroesophageal reflux disease
<b>H<sup>+</sup></b>	: Hydrogen Ion
<b>H2RA</b>	: histamine-2 receptor antagonist
<b>HDL</b>	: High density lipoprotein
<b>IL 6</b>	: Interleukin 6
<b>K<sup>+</sup></b>	: Potassium Ion
<b>LDL</b>	: Low density lipoprotein
<b>LES</b>	: Lower esophageal sphincter
<b>LESRs</b>	: Lower Esophageal Sphincter Relaxations
<b>MRI</b>	: Magnetic resonance imaging
<b>NERD</b>	: Non erosive reflux disease
<b>RDAs</b>	: recommended daily allowances
<b>TNF</b>	: Tumor necrosis factor
<b>WHO</b>	: World Health Organization
<b>5-HT<sub>3</sub></b>	: Histamine

## List of Tables

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
<b>Table (1):</b>	Modulator of lower esophageal sphincter pressure.....	14
<b>Table (2):</b>	The mean of age in each group .....	140
<b>Table (3):</b>	Comparison between the four groups as regard gender .....	141
<b>Table (4):</b>	Comparison between the four studied groups as regard of BMI.....	142
<b>Table (5):</b>	Comparison between four groups as regard of central obesity .....	143
<b>Table (6):</b>	Comparison between the four groups as regard of mean waist circumference.....	143
<b>Table (7):</b>	Comparison between the four studied groups as regard the mean IL 6 .....	145
<b>Table (8):</b>	Different findings in upper gastrointestinal endoscopy and its percentage in each group. ....	146
<b>Table (9):</b>	Comparison between IL6 level and different finding in upper gastrointestinal endoscopy.....	148
<b>Table (10):</b>	Comparison between BMI and upper gastrointestinal endoscopy findings. ....	149
<b>Table (11):</b>	Comparison between central obesity and BMI, IL6. The statical finding is no relationship between central obesity and each of them.....	150
<b>Table (12):</b>	Realation between IL 6 and age ,BMI ,central obesity and waist circumfreanc .....	151
<b>Table (13):</b>	ROC curve between patients and controls as regard IL-6.....	153

## List of Figures

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
<b>Figure (1):</b>	Anatomy of then gastroesophageal junction illustrating the major elements of the antireflux barrier .....	13
<b>Figure (2):</b>	Neurocircuit related to pathogenesis of obesity .....	55
<b>Figure (3):</b>	Types of body shapes.....	60
<b>Figure (4):</b>	Energy balance equation.....	65
<b>Figure (5):</b>	Gastric electrical-stimulation device. ....	112
<b>Figure (6):</b>	Four groups as regard age.....	140
<b>Figure (7):</b>	Comparison between the four groups as regard gender .....	141
<b>Figure (8):</b>	Range of BMI in four groups.....	142
<b>Figure (9):</b>	Central obesity is highly positive in group I and group III and highly negative in group II and group IV.....	143
<b>Figure (10):</b>	Mean of waist cirmfreance in each groups ....	145
<b>Figure (11):</b>	IL6 range in each group. ....	146
<b>Figure (12):</b>	Percentage of different GIT endoscopy findings in each group .....	147
<b>Figure (13):</b>	Significant difference as regard mean IL6 concentration among different GIT upper endoscopy. ....	148
<b>Figure (14):</b>	Relationship between BMI and upper GIT endoscopy finding.....	150

**Figure (15):** Relation between central obesity and BMI, and IL6. The finding is no relationship between central obesity and each of them ..... 151

### **List of Figures (Cont...)**

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
<b>Figure (16):</b>	The sensitivity and specificity of IL6 in GERD patients .....	152
<b>Figure (17):</b>	ROC curve between patients and controls as regard IL-6.....	153



## Introduction

Gastroesophageal reflux (GERD) is a normal physiological phenomenon experienced intermittently by most people, it occurs when the amount of gastric juice that refluxes into the esophagus exceeds the normal limit causing symptoms either with mucosal injury i.e. esophagitis (GERD) or without remarkable oesophageal lesion i.e. non erosive reflux disease (NERD) (*Loots et al., 2013*).

GERD is a disorder that affects the lower esophageal sphincter (LES), and causes injury to the esophagus due to chronic exposure to acid. Several factors contribute to the weakening of the LES as some food and smoking but one of the most common causes of GERD is obesity (*Janeway et al., 2007*).

Obesity is a medical condition in which excess fat has accumulated to the extent that it may cause an adverse effect on health, leading to reduced life expectancy and/or increased health problems. BMI is one of the methods used to estimate obesity where the subject considered obese when his BMI exceeds  $30\text{kg/m}^2$  (*Haslam and James, 2005*).

Studies proved that; GERD and its complication is highly related to high BMI. Therefore, the pathophysiology of GERD in patients who are morbidly obese might differ from that of patients who are not obese So that the correction of reflux in patients who are morbidly obese might be better achieved with a procedure that first controls obesity (*Kaplan, 2008*).

---

The mechanism by which a high BMI increases GERD is not completely understood. Increased intragastric pressure and gastroesophageal pressure gradient, incompetence of the lower esophageal sphincter (LES), and increased frequency of transient LES relaxations may all play a role in the pathophysiology of GERD in patients who are morbidly obese (*Kaplan, 2008*).

Studies have focused that visceral fat is metabolically active and produce variety of cytokines including IL-6 and TNF which may affect oesophagogastric motor activity (*Friedenberg, et al., 2008*).

Interleukin-6 (IL-6) is a protein that in humans is encoded by the *IL6* gene. It is an interleukin that acts as both a pro-inflammatory and anti-inflammatory cytokine. It is secreted by T cells and macrophages to stimulate immune response, e.g. during infection and after trauma, other tissue damage leading to inflammation. In terms of host response to a foreign pathogen during infection, IL-6 has been shown, to be required for resistance against the bacterium, *Streptococcus pneumoniae*. IL-6 is also a "myokine," a cytokine produced from muscle, and is elevated in response to muscle contraction (*Febbraio and Pedersen, 2005*).



## **AIM OF THE Work**

**T**he aim of this study is to assess the possible role of IL-6 in GERD patients with and without obesity.

## Chapter (1)

# Gastroesophageal Reflux Disease (GERD)

Gastroesophageal reflux is a normal physiologic phenomenon experienced intermittently by most people, particularly after a meal. Gastroesophageal reflux disease (GERD) occurs when the amount of gastric juice that refluxes into the esophagus exceeds the normal limit, causing symptoms with or without associated esophageal mucosal injury (i.e., esophagitis) (*Loots et al., 2013*).

Gastroesophageal reflux disease is the failure of the normal anti-reflux barrier to protect against frequent and abnormal amount of gastric content moving retrograde effortlessly from stomach to esophagus. GERD itself is not a disease but rather physiological process. It occurs multiple times each day especially after large meals without producing symptom of heartburn or mucosal damage. In contrast GERD is a spectrum of disease usually producing symptoms of heartburn and acid regurgitation. Most patients have no visible damage at the time of endoscopy (non-erosive GERD), whereas others have esophagitis, peptic stricture, Barrett's esophagus, or have chest pain or evidence of extra esophageal manifestation such as pulmonary or near, nose, and throat symptoms. GERD is multifactorial process and most common disease of mankind (*Orenstein et al., 2002*).

## **Epidemiology**

Although GERD is widely reported to be one of the most prevalent diseases of gastrointestinal tract, prevalence and incidence data for it based more on estimates than actual data. Furthermore estimating the prevalence of GERD differs depending on whether the analysis based on symptoms (usually heartburn) or sign of disease (i.e., esophagitis) (*Ohara et al., 2011*).

On basis of symptoms GERD is common in western countries. In nationwide population-based study by Gallup Organization in United States, 44% of respondents reported heartburn at least once a month (*Locke et al., 1997*).

In contrast the true prevalence of esophagitis is very difficult to define as healthy person rarely undergo upper endoscopy. Studies suggest that 7% of American have erosive esophagitis, whereas Europeans studies identify prevalence rate ranging from 2% to 10% (*McCord and Clouse, 1981*). The gender ratio of GERD show nearly equal proportion of affected men and women, but a male predominance occurs in esophagitis and Barrett's esophagus. Increasing age is important factor in prevalence of GERD complications, probably the result of cumulative acid injury over time to esophagus (*Johnson and Fennerty, 2004*).

Studies suggest that many patients with H-pylori induced gastritis have involvement of both the antrum and corpus decreasing parietal cell mass, reducing acid secretions no

elevating gastric PH. (El-serage HB, Sonnenberg A 1998) This may have a protective effect on esophageal mucosa in patients susceptible to GERD. Additionally, the epidemic increase in obesity may be another contributing factor for GERD (*Mokdad et al., 2001*).

Along with environmental factor, the epidemiology of GERD may be affected by genetics. Families clustering of GERD and its complications, especially Barrett's esophagitis have been reported (*Romero et al., 1997*). The genetic mechanisms are unknown but may be related to smooth muscle disorder associated with hiatal hernia, lower esophageal sphincter (LES) pressure and impaired esophageal motility (*Orenstein et al., 2002*).

### **Health care impact**

Although rarely a cause of death, GERD is associated with considerable morbidity and complications such as esophageal ulceration (5%), peptic stricture (4% to 20%) and Barrett's esophagitis (8% to 20%) (*Johnson and Fennerty, 2004*). Not surprisingly the burden of GERD on health care use is great. In study using national ambulatory medical care survey for year 2000, heartburn and dyspepsia were identified as the fifth most gastrointestinal complaint, prompting more than 1.8 million outpatient visits. Abdominal pain was the leading outpatient gastrointestinal diagnosis followed closely by GERD with 4.5 million visits (*Edwards et al., 1992*).

## **Pathogenesis**

The pathogenesis of GERD is complex, resulting from an imbalance between defensive factors protecting the esophagus (antireflux barriers, esophageal acid clearance, tissue resistance) and aggressive factors from stomach (gastric acidity, volume, and duodenal content).

## **Antireflux Barriers**

The first tier of the three-tiered esophageal defense against acid damage consists of the antireflux barriers. This is an anatomically complex region including the intrinsic LES, diaphragmatic crura, and the intra-abdominal location of the LES, the phrenoesophageal ligaments, and the acute angle of His (fig. 1).

The LES involves the distal 3 to 4 cm of the esophagus and at rest is tonically contracted (*Liebermann-Nleffert et al., 1979*). It is the major component of the antireflux barrier, being capable of preventing reflux even when completely displaced from the diaphragmatic crura by a hiatal hernia (*Sloan et al., 1992*).

The proximal LES border is normally 1.5 to 2 cm above the squamocolumnar junction, whereas the distal segment, about 2 cm in length, lies within the abdominal cavity. This location maintains gastro esophageal competence during intra-abdominal pressure events. Resting LES pressure ranges from 10 to 30 mm Hg with a generous reserve capacity, as only a pressure of 5 to 10 mm Hg is necessary to prevent GERD (*Dodds et al., 1981*). The LES maintains a high pressure zone